CDSCO Drug Brand Name Extension Proposal: Everything Pharma Companies Need to Know

The Central Drugs Standard Control Organisation (CDSCO) has initiated a public consultation on the use of drug brand name extensions by pharmaceutical companies in India. Through a public notice issued on 6 July 2026, the national drug regulator has invited comments from stakeholders on whether pharmaceutical firms should continue using the same parent brand name for medicines containing different active pharmaceutical ingredients (APIs).

The proposal follows discussions held during the 67th Drugs Consultative Committee (DCC) Meeting on 17 November 2025, where concerns were raised regarding the potential for confusion arising from the use of similar brand names for different medicines. It is important to note that this is only a consultation proposal and not a new regulation or ban. CDSCO is seeking feedback before making any policy decision.

What is the CDSCO Proposal?

CDSCO has published a public notice titled "Inviting comments on consideration of the proposal regarding issue of use of brand name extensions by the pharmaceutical firms." The consultation aims to gather views from pharmaceutical companies, industry associations, healthcare professionals, consumer groups, and other stakeholders regarding the practice of extending established drug brand names to different pharmaceutical products.

The issue was referred to CDSCO following recommendations made by the Drugs Consultative Committee (DCC), which suggested that the matter should be discussed with stakeholders before any regulatory action is considered.

What Are Drug Brand Name Extensions?

A brand name extension is a marketing practice in which a pharmaceutical company uses an existing and well-recognised brand name for multiple products by adding a suffix or modifier. For example -

• Brand ABC
• Brand ABC Plus
• Brand ABC Forte
• Brand ABC Advance

In some cases, these medicines may contain different active pharmaceutical ingredients or be intended for different therapeutic uses. While this approach may help companies build brand recognition, it has also raised questions regarding product identification and differentiation.

Why is CDSCO Reviewing This Practice? According to the discussions recorded during the 67th DCC meeting, concerns were raised that medicines marketed under similar brand names but containing different APIs could create confusion among healthcare professionals and consumers.

The committee observed that the issue requires broader consultation with stakeholders before any decision is taken. As a result, CDSCO has invited public comments to understand the industry's views, practical challenges, and possible regulatory approaches. The current consultation is therefore aimed at collecting feedback rather than introducing immediate restrictions.

Current Regulatory Position

At present, no new rule has been implemented regarding drug brand name extensions. The CDSCO notice is only a request for stakeholder comments. Pharmaceutical companies can continue operating under the existing regulatory framework until any official guideline or amendment is notified by the regulator.

Stakeholders were requested to submit their comments within the timeline specified in the public notice so that CDSCO can consider all viewpoints before finalising its decision.

Who Should Pay Attention?

The proposal is particularly relevant for -

• Pharmaceutical manufacturers
• Marketing authorisation holders
• Drug marketing companies
• Regulatory affairs professionals
• Brand management teams
• Healthcare industry associations

Companies with multiple products marketed under a common parent brand may wish to review their portfolios and assess whether future regulatory changes could impact their branding strategy.

Possible Industry Impact

Although CDSCO has not proposed any immediate compliance requirement, the consultation could influence future pharmaceutical branding practices in India. If the regulator decides to issue new guidelines after reviewing stakeholder feedback, pharmaceutical companies may need to -

• Review existing product brand names.
• Assess medicines marketed under common parent brands.
• Evaluate future product naming strategies.
• Ensure compliance with any revised CDSCO requirements.

Since no final decision has been announced, these remain possible considerations rather than confirmed regulatory obligations.

Importance of Stakeholder Consultation

Public consultations are an important part of India's regulatory process. They allow regulators to receive practical feedback from industry experts, manufacturers, healthcare professionals, and consumers before introducing significant policy changes.

By inviting comments on the proposal, CDSCO aims to ensure that any future decision is balanced, practical, and considers both patient interests and industry concerns. Such consultations also help identify implementation challenges that may not be evident during committee discussions alone.

Key Takeaways

• CDSCO issued a public consultation notice on 6 July 2026 regarding the use of drug brand name extensions.
• The proposal follows recommendations made during the 67th Drugs Consultative Committee (DCC) Meeting held on 17 November 2025.
• The regulator is seeking stakeholder comments before making any regulatory decision.
• The consultation relates to medicines marketed under similar parent brand names while containing different active pharmaceutical ingredients.
• No ban, restriction, or new regulation has been introduced at this stage.

Conclusion

The CDSCO Drug Brand Name Extension Proposal represents the beginning of a regulatory review rather than the introduction of a new compliance requirement. The consultation demonstrates the regulator's intention to evaluate current pharmaceutical branding practices by gathering views from industry stakeholders and healthcare professionals. For pharmaceutical companies, this is an opportunity to participate in the consultation process and stay informed about potential regulatory developments. Until CDSCO issues any final notification or guideline, the existing regulatory framework remains unchanged. Businesses should continue monitoring official CDSCO announcements to understand the outcome of the consultation and prepare for any future policy changes.